Market News AIOpen the app

Truist Securities says to keep buying Viridian Therapeutics and raised its price target to $42.

OpinionRead the original at tradingview.com
Neutral

Truist kept its Buy rating on Viridian, but this is an analyst view, not a change in the company's business. The report gives no new results or company developments, so it does not shift the outlook.

VRDN · Viridian Therapeutics, Inc.

AI read · Neutral

The AI's read

A continued positive view from Truist shows support, but this update confirms an existing rating rather than reporting a new change at Viridian. It gives no details about the third-quarter results or other company news to show that Viridian's outlook has shifted.

Get alerts for VRDN

Follow Viridian Therapeutics, Inc. (VRDN) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for VRDN
Free on the App Store and Google Play, or on the web.